These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 21740073)

  • 1. A reappraisal of current dosing strategies for intravenous fosfomycin in children and neonates.
    Traunmüller F; Popovic M; Konz KH; Vavken P; Leithner A; Joukhadar C
    Clin Pharmacokinet; 2011 Aug; 50(8):493-503. PubMed ID: 21740073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: what is the evidence on dosing regimens?
    Dimopoulos G; Koulenti D; Parker SL; Roberts JA; Arvaniti K; Poulakou G
    Expert Rev Anti Infect Ther; 2019 Mar; 17(3):201-210. PubMed ID: 30668931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies.
    Antonello RM; Di Bella S; Maraolo AE; Luzzati R
    Eur J Clin Microbiol Infect Dis; 2021 Jun; 40(6):1117-1126. PubMed ID: 33604721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections.
    Roussos N; Karageorgopoulos DE; Samonis G; Falagas ME
    Int J Antimicrob Agents; 2009 Dec; 34(6):506-15. PubMed ID: 19828298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections.
    Wangchinda W; Pogue JM; Thamlikitkul V; Leelawattanachai P; Koomanachai P; Pai MP
    J Antimicrob Chemother; 2024 Jun; 79(6):1372-1379. PubMed ID: 38597137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli.
    Merino-Bohórquez V; Docobo-Pérez F; Sojo J; Morales I; Lupión C; Martín D; Cameán M; Hope W; Pascual Á; Rodríguez-Baño J
    Clin Microbiol Infect; 2018 Nov; 24(11):1177-1183. PubMed ID: 29649596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fosfomycin as a potential therapy for the treatment of systemic infections: a population pharmacokinetic model to simulate multiple dosing regimens.
    Ortiz Zacarías NV; Dijkmans AC; Burggraaf J; Mouton JW; Wilms EB; van Nieuwkoop C; Touw DJ; Kamerling IMC; Stevens J
    Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New perspectives for reassessing fosfomycin: applicability in current clinical practice.
    Candel FJ; Matesanz David M; Barberán J
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):1-7. PubMed ID: 31131586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous fosfomycin for the treatment of patients with central nervous system infections: evaluation of the published evidence.
    Tsegka KG; Voulgaris GL; Kyriakidou M; Falagas ME
    Expert Rev Anti Infect Ther; 2020 Jul; 18(7):657-668. PubMed ID: 32397774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deciphering pharmacokinetics and pharmacodynamics of fosfomycin.
    Rodríguez-Gascón A; Canut-Blasco A
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):19-24. PubMed ID: 31131588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous fosfomycin for the treatment of hospitalized patients with serious infections.
    Shorr AF; Pogue JM; Mohr JF
    Expert Rev Anti Infect Ther; 2017 Oct; 15(10):935-945. PubMed ID: 28901793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative pharmacokinetics of fosfomycin in the neonate: 2 modes of administration].
    Guibert M; Magny JF; Poudenx F; Lebrun L; Dehan M
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):750-2. PubMed ID: 3309809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review.
    Parker S; Lipman J; Koulenti D; Dimopoulos G; Roberts JA
    Int J Antimicrob Agents; 2013 Oct; 42(4):289-93. PubMed ID: 23880170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic models of first choice beta-lactam antibiotics for severe infections treatment: What antibiotic regimen to prescribe in children?
    Marsot A
    J Pharm Pharm Sci; 2020; 23():470-485. PubMed ID: 33227230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fosfomycin: Resurgence of an old companion.
    Sastry S; Doi Y
    J Infect Chemother; 2016 May; 22(5):273-80. PubMed ID: 26923259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues.
    Frossard M; Joukhadar C; Erovic BM; Dittrich P; Mrass PE; Van Houte M; Burgmann H; Georgopoulos A; Müller M
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2728-32. PubMed ID: 10991852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.
    Li G; Standing JF; Bielicki J; Hope W; van den Anker J; Heath PT; Sharland M
    Drugs; 2017 Jun; 77(9):941-950. PubMed ID: 28456943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model.
    VanScoy B; McCauley J; Bhavnani SM; Ellis-Grosse EJ; Ambrose PG
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5141-5. PubMed ID: 27270274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Neonates and Young Infants.
    Tang BH; Wu YE; Kou C; Qi YJ; Qi H; Xu HY; Leroux S; Huang X; Zhou Y; Zheng Y; Jacqz-Aigrain E; Shen AD; Zhao W
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-Exposure Simulation for Piperacillin-Tazobactam Dosing Strategies in Infants and Young Children.
    Thibault C; Kassir N; Théorêt Y; Varin F; Litalien C; Autmizguine J
    J Popul Ther Clin Pharmacol; 2017 Aug; 24(3):e33-344. PubMed ID: 28873292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.